» Articles » PMID: 23962296

25-(OH)VitD3, As a Risk Indicator in Diagnosis of Adenocarcinoma

Overview
Specialty Pharmacology
Date 2013 Aug 22
PMID 23962296
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Vitamin D (VitD) comes from sunlight exposure and food intake. Apart from regulating calcium homeostasis and bone function, its levels also associate with the presence of development of adenocarcinoma. VitD can interact with VitD receptor (VDR), which heterodimerizes with retinoic X receptor (RXR) and then induces transcription of proteins that function in cell proliferation, differentiation, apoptosis, and angiogenesis. We reviewed and discussed the genes and their associated polymorphisms involved in the correlation between development of adenocarcinoma and VitD deficiency to highlight how VitD may be instrumental in cancerization. Furthermore, pilot epidemiological data show that the detection of 25-hydroxy-Vitamin D3 ((36.5±10.7 nmol/L, n=129) vs (81.4±19.8 nmol/L, n=81)) can be a promising approach in cancer diagnosis. In this review, we suggest that 25-hydroxy-Vitamin D3 can act as an indicator and/or risk assessment factor in early diagnosis, prognosis and treatment of adenocarcinoma.

Citing Articles

1,25-Dihydroxyvitamin D affects gastric cancer progression by repressing BMP3 promoter methylation.

Zhao Y, Cai L, Wang H, Shi X, Ye H, Song P Onco Targets Ther. 2019; 12:2343-2353.

PMID: 30992671 PMC: 6445188. DOI: 10.2147/OTT.S195642.